BridgeMD
Metycor study
EU CTIS ID: 2024-514143-28-00
What this study is testing
Assess improvement in hypertension, glucose metabolism, and cortisol levels in patients with ACS measured before and after a 6 months treatment trial with Metycor.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Must be at least 18 years of age.
- • Patients with ACS and one or more metabolic-, bone- and / or psychiatric complications.
- • The patient is eligible for surgical treatment with adrenalectomy
- • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
You likely can't join if
- • Patients with fulminant Cushing syndrome, who should be given priority for prompt surgery
- • Patients treated with Metycor at present, or before
- • Patinents treated with other cortisol lowering drugs
- • Patients hypersensitive/allergic to some of the substances in Metycor
- • The patient is not able to collaborate on the follow-up in the study
- • Women who are breastfeeding
See the full eligibility criteria
- • Must be at least 18 years of age.
- • Patients with ACS and one or more metabolic-, bone- and / or psychiatric complications.
- • The patient is eligible for surgical treatment with adrenalectomy
- • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
- • Patients with fulminant Cushing syndrome, who should be given priority for prompt surgery
- • Patients treated with Metycor at present, or before
- • Patinents treated with other cortisol lowering drugs
- • Patients hypersensitive/allergic to some of the substances in Metycor
- • The patient is not able to collaborate on the follow-up in the study
- • Women who are breastfeeding
- • Pregnant women
- • Patients with pituitary Cushing disease
- • Patients with low dexamethasone bioavailability as a reason for their positive Dexamethasone suppression test.
- • Patients using oral estrogens
- • Patients with adrenal insufficiency
- • Patients with adrenocortical carsinomas
- • Patients with co-secretion of aldosterone
- • Patients with present or previous hearth disease
- • Patients with electrolyte disturbances
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.